You are here

  • Home
  • Archive
  • Volume 7, Issue 1
  • Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors

Article metrics

Article menu

Download PDFPDF

Research Article
Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors

 

Online download statistics by month:

Online download statistics by month: December 2019 to April 2025

AbstractFullPdf
Dec 201920200
Jan 202014214215
Feb 20201001003
Mar 202054544
Apr 2020646413
May 202010410410
Jun 2020545411
Jul 202036367
Aug 2020727275
Sep 2020777734
Oct 2020424132
Nov 2020777732
Dec 2020686838
Jan 2021767552
Feb 2021464637
Mar 202110510541
Apr 2021828241
May 2021797940
Jun 2021555524
Jul 2021525225
Aug 2021393923
Sep 2021555536
Oct 2021595958
Nov 2021535341
Dec 2021575736
Jan 2022526039
Feb 2022273130
Mar 2022485742
Apr 2022596346
May 2022414241
Jun 2022597141
Jul 2022464822
Aug 2022474822
Sep 2022475344
Oct 2022383928
Nov 20225710039
Dec 2022464535
Jan 2023656537
Feb 2023535339
Mar 2023696937
Apr 2023444543
May 2023414126
Jun 2023646533
Jul 2023454540
Aug 2023495028
Sep 202312312324
Oct 202328929024
Nov 202345847140
Dec 2023267267273
Jan 20248686124
Feb 2024838321
Mar 202410310138
Apr 2024697040
May 202410911551
Jun 2024818442
Jul 202412812943
Aug 2024707228
Sep 2024606046
Oct 2024878750
Nov 202411311446
Dec 2024829048
Jan 20251019944
Feb 2025878843
Mar 2025798036
Apr 202510510536
Total524553702537